Articles
Vol. 4 No. 2 (2026)
Transcatheter tricuspid valve repair for tricuspid regurgitation: a meta-analysis of MitraClip, TriClip,and PASCAL Systems
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: 1 July 2026
185
Views
15
Downloads
Authors
Tricuspid regurgitation (TR) is associated with significant morbidity and mortality, yet surgical intervention remains underutilized due to high operative risk. Transcatheter tricuspid valve repair (TTVr) has emerged as a less invasive alternative; however, comparative data across device platforms remain limited. We conducted a systematic review and meta-analysis in accordance with PRISMA guidelines, searching PubMed/MEDLINE, Embase, and Cochrane Library up to March 2026. Studies evaluating TTVr using MitraClip, TriClip, or PASCAL in adults with moderate-to-severe TR were included. Primary outcomes included changes in TR severity and echocardiographic parameters (TR volume, vena contracta, effective regurgitant orifice area, tricuspid annular plane systolic excursion). Secondary outcomes included 6-minute walk distance (6MWD) and New York Heart Association (NYHA) functional class. A random-effects model was used for pooled analyses. Fifty studies were included in the meta-analysis. TTVr significantly reduced TR volume (MD −21.53 mL; 95% CI −24.72 to −18.35) and vena contracta (MD −5.91 mm; 95% CI −7.62 to −4.19), with consistent improvements across devices. Severe TR was significantly reduced (RR 0.32; 95% CI 0.26-0.39). Functional outcomes improved, with increased 6MWD (MD 36.14 m; 95% CI 23.85-48.43) and a higher proportion of patients achieving NYHA class I/II. A modest decline in TAPSE was observed (MD −0.74 mm). Subgroup analyses showed no significant differences in most echocardiographic outcomes, though functional improvements varied among devices. We concluded that TTVr is associated with significant improvements in TR severity, echocardiographic parameters, and functional status. Comparable outcomes across MitraClip, TriClip, and PASCAL suggest a potential class effect, supporting TTVr as an effective treatment option for high-risk patients.
Downloads
Download data is not yet available.
Citations
1. Nath J, Foster E, Heidenreich PA. Impact of tricuspid regurgitation on long-term survival. J Am Coll Cardiol 2004;43:405-9.
2. Dreyfus GD, Martin RP, Chan KMJ, et al. Functional tricuspid regurgitation: a need to revise our understanding. J Am Coll Cardiol 2015;65:2331-6.
3. Taramasso M, Alessandrini H, Latib A, et al. Outcomes after current transcatheter tricuspid valve intervention: mid-term results from the International TriValve Registry. JACC Cardiovasc Interv 2019;12:155-65.
4. Nickenig G, Weber M, Lurz P, et al. Transcatheter edge-to-edge repair for reduction of tricuspid regurgitation: 6-month outcomes of the TRILUMINATE single-arm study. Lancet 2019;394:2002-11.
5. Fam NP, Braun D, von Bardeleben RS, et al. Compassionate use of the PASCAL transcatheter valve repair system for severe tricuspid regurgitation. JACC Cardiovasc Interv 2019;12:2488-95.
6. Wells GA, Shea B, O’Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa: Ottawa Hospital Research Institute; 2011.
7. Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 2019;366:l4898.
8. Slim K, Nini E, Forestier D, et al. Methodological index for non-randomized studies (MINORS): development and validation of a new instrument. ANZ J Surg 2003;73:712-6.
9. Orban M, Besler C, Braun D, et al. Right ventricular function after transcatheter tricuspid repair. JACC Cardiovasc Interv 2019;12:559-70.
10. Lurz P, Stephan von Bardeleben R, Weber M, et al. Transcatheter edge-to-edge repair for tricuspid regurgitation (TRILUMINATE). Lancet 2021;398:2027-38.
11. Abushouk AI, Layoun H, Harb SC, et al. Real-world patient eligibility and feasibility of transcatheter edge-to-edge repair or replacement interventions for tricuspid regurgitation. J Card Fail 2024;30:1265-72.
12. Ali FM, Ong G, Edwards J, et al. Comparison of transcatheter tricuspid valve repair using the MitraClip NTR and XTR systems. Int J Cardiol 2021;327:156-62.
13. Aurich M, Volz MJ, Mereles D, et al. Initial experience with the PASCAL Ace implant system for treatment of severe tricuspid regurgitation. Circ Cardiovasc Interv 2021;14:e010770.
14. Baldus S, Schofer N, Hausleiter J, et al. Transcatheter valve repair of tricuspid regurgitation with the PASCAL system: TriCLASP study 30-day results. Catheter Cardiovasc Interv 2022;100:1291-9.
15. Cai S, Bowers N, Dhoot A, Ho EC, et al. Natural history of severe tricuspid regurgitation: outcomes after transcatheter tricuspid valve intervention compared to medical therapy. Int J Cardiol 2020;320:49-54.
16. Carpenito M, Cammalleri V, Vitez L, et al. Edge-to-edge repair for tricuspid valve regurgitation. J Clin Med 2022;11:5609.
17. Cepas-Guillen PL, De La Fuente Mancera JC, Bofarull G, et al. Initial results after the implementation of an edge-to-edge transcatheter tricuspid valve repair program. J Clin Med 2021;10:4252.
18. Davidson CJ, Lim DS, Smith RL, et al. Early feasibility study of the Cardioband tricuspid system for functional tricuspid regurgitation: 30-day outcomes. JACC Cardiovasc Interv 2021;14:41-50.
19. Donal E, Lurz P, Schuler R, et al. Real-world outcomes for tricuspid edge-to-edge repair: initial echocardiographic results from the TriClip bRIGHT study. Eur Heart J Cardiovasc Imaging. 2022.
20. Donal E, Lurz P, Maisano F, et al. Transcatheter edge-to-edge repair for severe isolated tricuspid regurgitation: the Tri.Fr randomized clinical trial. JAMA 2025;333:124-32.
21. Dumitriu Carcoana AO, Scoma CB, Maletz SN, et al. Most hospitalized patients with significant tricuspid regurgitation have advanced disease preventing transcatheter tricuspid valve intervention. Cardiovasc Revasc Med 2024;65:18-4.
22. Fam NP, Braun D, von Bardeleben RS, et al. Compassionate use of the PASCAL transcatheter valve repair system for severe tricuspid regurgitation. JACC Cardiovasc Interv 2019;12:2488-95.
23. Freixa X, Arzamendi D, Del Trigo M, et al. The TriClip system for edge-to-edge transcatheter tricuspid valve repair: a Spanish multicenter study. Rev Esp Cardiol (Engl Ed) 2022;75:797-804.
24. Hellhammer K, Schueler R, Eißmann M, et al. Safety of transesophageal echocardiography during transcatheter edge-to-edge tricuspid valve repair. Front Cardiovasc Med 2022;9:856028.
25. Kalbacher D, Schäfer U, Bardeleben RS von, et al. Impact of tricuspid valve regurgitation in surgical high-risk patients undergoing MitraClip implantation: results from the TRAMI registry. EuroIntervention 2017;12:e1809-16.
26. Kar S, Hahn RT, Narang N, et al. Two-year outcomes of transcatheter edge-to-edge repair for severe tricuspid regurgitation: the TRILUMINATE pivotal randomized controlled trial. Circulation 2025;151:1630-8.
27. Karam N, Mehr M, Taramasso M, et al. Impact of transcatheter tricuspid valve repair for severe tricuspid regurgitation on kidney and liver function. JACC Cardiovasc Interv 2019;12:1413-20.
28. Kitamura M, Fam NP, Braun D, et al. 12-month outcomes of transcatheter tricuspid valve repair with the PASCAL system for severe tricuspid regurgitation. Catheter Cardiovasc Interv 2021;97:1281-9.
29. Kitamura M, Kresoja KP, Balata M, et al. Health status after transcatheter tricuspid valve repair in patients with functional tricuspid regurgitation. JACC Cardiovasc Interv 2021;14:2545-56.
30. Kodali S, Hahn RT, Eleid MF, et al. Feasibility study of the transcatheter valve repair system for severe tricuspid regurgitation. J Am Coll Cardiol 2021;77:345-56.
31. Kodali S, Hahn RT, George I, et al. Transfemoral tricuspid valve replacement in patients with tricuspid regurgitation: TRISCEND study 30-day results. JACC Cardiovasc Interv 2022;15:471-80.
32. Körber MI, Landendinger M, Gerçek M, et al. Transcatheter treatment of secondary tricuspid regurgitation with direct annuloplasty. Circ Cardiovasc Interv 2021;14:e010019.
33. Kresoja KP, Lauten A, Landmesser U, et al. Transcatheter tricuspid valve repair in the setting of heart failure with preserved or reduced left ventricular ejection fraction. Eur J Heart Fail 2020;22:1817-25.
34. Krikken JA, van den Heuvel AFM, Willemsen HM, et al. Transcatheter edge-to-edge repair of tricuspid regurgitation in the Netherlands. Neth Heart J 2022;30:393-9.
35. Löw A, von Bardeleben RS, Sorajja P, et al. Acute and short-term results of MitraClip XTR vs. PASCAL transcatheter valve repair system for severe tricuspid regurgitation. Struct Heart 2021.
36. Lurz P, Besler C, Noack T, et al. Transcatheter treatment of tricuspid regurgitation using edge-to-edge repair. EuroIntervention 2018;14:645-53.
37. Lurz P, Stephan von Bardeleben R, Weber M, et al. Transcatheter edge-to-edge repair for treatment of tricuspid regurgitation. J Am Coll Cardiol 2021;77:229-39.
38. Mahowald MK, Nishimura RA, Pislaru SV, et al. Reduction in right atrial pressures is associated with hemodynamic improvements after transcatheter edge-to-edge repair of the tricuspid valve. Circ Cardiovasc Interv 2021;14:e010557.
39. Mehr M, Taramasso M, Besler C, et al. 1-year outcomes after edge-to-edge valve repair for symptomatic tricuspid regurgitation: results from the TriValve Registry. JACC Cardiovasc Interv 2019;12:145-54.
40. Meijerink F, Koch KT, de Winter RJ, et al. Transcatheter tricuspid valve repair: early experience in the Netherlands. Neth Heart J 2021;29:595-603.
41. Nickenig G, Kowalski M, Hausleiter J, et al. Transcatheter treatment of severe tricuspid regurgitation with the edge-to-edge MitraClip technique. Circulation 2017;135:1802-14.
42. Nickenig G, Weber M, Lurz P, et al. Transcatheter edge-to-edge repair for reduction of tricuspid regurgitation: 6-month outcomes of the TRILUMINATE single-arm study. Lancet. 2019;394:2002-11.
43. Nickenig G, Friedrichs KP, Baldus S, et al. Thirty-day outcomes of the Cardioband tricuspid system for patients with symptomatic functional tricuspid regurgitation: the TriBAND study. EuroIntervention 2021;17:809-17.
44. Ohno Y, Attizzani GF, Capodanno D, et al. Association of tricuspid regurgitation with clinical and echocardiographic outcomes after percutaneous mitral valve repair with the MitraClip system. Eur Heart J Cardiovasc Imaging 2014;15:1240-8.
45. Orban M, Braun D, Orban M, et al. Six-month outcome after transcatheter edge-to-edge repair of severe tricuspid regurgitation in patients with heart failure. Eur J Heart Fail 2018;20:1055-62.
46. Orban M, Braun D, Deseive S, et al. Transcatheter edge-to-edge tricuspid repair for severe tricuspid regurgitation reduces hospitalizations for heart failure. JACC Heart Fail 2020;8:265-76.
47. Otto S, Velichkov M, Hamadanchi A, et al. The impact of tricuspid annular geometry on outcome after percutaneous edge-to-edge repair for severe tricuspid regurgitation. Cardiol J 2021;28:579-88.
48. Planer D, Beeri R, Danenberg HD. First-in-human transcatheter tricuspid valve repair: 30-day follow-up experience with the Mistral device. JACC Cardiovasc Interv 2020;13:2091-6.
49. Ruf TF, Hahn RT, Kreidel F, et al. Short-term clinical outcomes of transcatheter tricuspid valve repair with the third-generation MitraClip XTR system. JACC Cardiovasc Interv 2021;14:1231-40.
50. Schlotter F, Stolz L, Kresoja KP, et al. Tricuspid regurgitation disease stages and treatment outcomes after transcatheter tricuspid valve repair. JACC Cardiovasc Interv. 2025
51. Sorajja P, Whisenant B, Hamid N, et al. Transcatheter repair for patients with tricuspid regurgitation. N Engl J Med 2023;388:1833-42.
52. Stocker TJ, Hertel D, Lurz P, et al. Cardiopulmonary hemodynamic profile predicts mortality after transcatheter tricuspid valve repair in chronic heart failure. JACC Cardiovasc Interv 2025;18:339-48.
53. Stolz L, Orban M, Besler C, et al. Cardiohepatic syndrome is associated with poor prognosis in patients undergoing tricuspid transcatheter edge-to-edge valve repair. JACC Cardiovasc Interv 2022;15:179-89.
54. Sugiura A, Tanaka T, Sato Y, et al. Leaflet configuration and residual tricuspid regurgitation after transcatheter edge-to-edge tricuspid repair. JACC Cardiovasc Interv 2021;14:2260-70.
55. Sugiura A, Kavsur R, Spieker M, et al. PASCAL versus MitraClip-XTR edge-to-edge device for the treatment of tricuspid regurgitation: a propensity-matched analysis. Clin Res Cardiol 2021;110:451-9.
56. Tang GHL, Nickenig G, Hahn RT, et al. Tricuspid transcatheter edge-to-edge repair for severe tricuspid regurgitation. J Am Coll Cardiol 2025;85:235-46.
57. Toyama K, Itatani K, Hoshino Y, et al. Postprocedural changes of tricuspid regurgitation after MitraClip therapy for mitral regurgitation. Am J Cardiol 2017;120:857-61.
58. Volz MJ, Weber M, Stephan von Bardeleben R, et al. Functional improvement following direct interventional leaflet repair of severe tricuspid regurgitation. ESC Heart Fail 2022;9:866-73.
59. Yzeiraj E, Lauten A, von Bardeleben RS, et al. Caval valve implantation for tricuspid regurgitation: results from the TRICAVAL trial. EuroIntervention. 2021;17:791-808.
How to Cite
1.
Abbas A, Jabbar A, Qamari SMH, Riaz H. Transcatheter tricuspid valve repair for tricuspid regurgitation: a meta-analysis of MitraClip, TriClip,and PASCAL Systems. Global Cardiol [Internet]. 2026 Jul. 1 [cited 2026 Jul. 11];4(2). Available from: https://www.globalcardiology.info/site/article/view/104
Copyright (c) 2026 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
